Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accelerate Diagnostics, IncAXDX · Entity 78156 | Director · 10% owner | December 03, 2024 | December 03, 2024 |
| Aspira Women's Health Inc.AWHL · Entity 7871 | 10% owner | June 05, 2026 | June 09, 2026 |
| BIODESIX INCBDSX · Entity 6053 | 10% owner · Emeritus Director | August 12, 2026 | August 13, 2026 |
| BIOLASE, INCBIOL · Entity 11470 | 10% owner | February 11, 2020 | May 15, 2020 |
| Neos Therapeutics, Inc.NEOS · Entity 141061 | 10% owner | February 17, 2017 | February 17, 2017 |
| QUIDEL CORP /DE/QDEL · Entity 126712 | Director · 10% owner | May 14, 2020 | May 18, 2020 |
| STERICYCLE INCSRCL · Entity 80873 | Director | April 30, 2018 | May 02, 2018 |
| YIELD10 BIOSCIENCE, INC.YTEN · Entity 88195 | 10% owner | December 20, 2023 | May 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accelerate Diagnostics, Inc
Report date December 03, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 8,310,388 |
Reported balance
After 2024-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-12-03 · Sale · Disposed 200,000 · Balance 8,310,388 F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes. F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust. |
| Common StockSEC Table I · non-derivative | Direct | 20,225 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,225 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,497 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,497 F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes.
F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.
F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Aspira Women's Health Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 4,046,051 |
Reported balance
After 2026-06-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-05 · Purchase · Acquired 222,222 · Balance 4,046,051 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2029-06-05 | IndirectBy Jack W. Schuler Living Trust | 300,000 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Purchase · Acquired 300,000 · Balance 300,000 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-09-17 | IndirectBy Jack W. Schuler Living Trust | 833,333 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 833,333 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2030-03-12 | IndirectBy Jack W. Schuler Living Trust | 1,801,265 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,801,265 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-07-26 | IndirectBy Jack W. Schuler Living Trust | 28,500 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 28,500 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-01-26 | IndirectBy Jack W. Schuler Living Trust | 8,888 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 8,888 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Common StockSEC Table I · non-derivative | Direct | 6,536 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,536 |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2027-07-09 | Direct | 6,536 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,536 |
Filing footnotes · ownership attribution and instrument terms
F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.
BIODESIX INC
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 555,810 |
Reported balance
After 2026-08-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-12 · Purchase · Acquired 15,000 · Balance 555,810 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler 2026 GRAT | 1,800,000 |
Reported balance
Holding disclosure · report date 2026-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,800,000 F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.
F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT.
BIOLASE, INC
Report date February 11, 2020 · Filed May 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 739,820 |
Reported balance
After 2020-02-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-02-11 · Sale · Disposed 1,307,931 · Balance 739,820 F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018. F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2020-02-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,000 F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018.
F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust.
Neos Therapeutics, Inc.
Report date February 17, 2017 · Filed February 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Jack W Schuler Living Trust | 2,338,671 |
Reported balance
Holding disclosure · report date 2017-02-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,338,671 F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
QUIDEL CORP /DE/
Report date May 14, 2020 · Filed May 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,103,249 |
Reported balance
After 2020-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-14 · Exercise / conversion · Acquired 2,100 · Balance 3,103,249 F1: Reflects release of restricted stock units that were previously reported on Form 4. F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-14 · Exercise / conversion · Disposed 2,100 · Balance 0 F3: Restricted stock units convert into common stock on a one-for-one basis. F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on Form 4.
F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any.
F3: Restricted stock units convert into common stock on a one-for-one basis.
F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date.
STERICYCLE INC
Report date April 30, 2018 · Filed May 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,078 |
Reported balance
After 2018-04-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-30 · Grant · Acquired 170 · Balance 2,078 F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.
YIELD10 BIOSCIENCE, INC.
Report date December 20, 2023 · Filed May 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 63,789 |
Reported balance
After 2023-12-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-12-20 · Sale · Disposed 36,000 · Balance 63,789 F1: This late filing is due to an inadvertent administrative error. F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split. F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This late filing is due to an inadvertent administrative error.
F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split.
F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date December 09, 2022 · Filed May 15, 2023
Section 16 reporting ended · disclosed 2023-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 36,595 |
Reported balance
After 2022-12-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-12-09 · Sale · Disposed 10,000 · Balance 36,595 F1: This late filing is due to an inadvertent administrative error. F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This late filing is due to an inadvertent administrative error.
F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2020 Filed Dec 10, 2020 02:42 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 35,157 | $6.83 | $240,122.31 |
DisclosureSEC source: 0000905148-20-001263 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 5,701,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F1 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 07, 2020 Filed Aug 3, 2021 22:43 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 65,782 | $1.91 | $125,367.34 |
DisclosureSEC source: 0000899243-21-031364 · doc4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,303,080 F1 · ownership.nature: The shares are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | Conversion3% Convertible Debt due June 2021 · Derivative | Not disclosed | $0.00 Strike: $14.40 | $10,586,622.58 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 14 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 0 Underlying: Common Stock · 753,735 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries H Preferred Stock · Derivative | 5,366,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 12 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 0 Underlying: Common Stock · 904,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries G Preferred Stock · Derivative | 9,419,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 11 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 0 Underlying: Common Stock · 1,586,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries F Preferred Stock · Derivative | 6,273,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 10 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 0 Underlying: Common Stock · 1,056,921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries E Preferred Stock · Derivative | 1,759,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 9 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 0 Underlying: Common Stock · 296,476 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries D Preferred Stock · Derivative | 3,101,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 8 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 0 Underlying: Common Stock · 522,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries C Preferred Stock · Derivative | 333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 7 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 0 Underlying: Common Stock · 56,155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries B-1 Preferred Stock · Derivative | 1,250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 6 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 0 Underlying: Common Stock · 245,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers give effect to such conversion. The B-1 Preferred Stock had no expiration date. F3 · derivative.exercise_date: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers give effect to such conversion. The B-1 Preferred Stock had no expiration date. F3 · derivative.expiration_date: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers give effect to such conversion. The B-1 Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries B Preferred Stock · Derivative | 1,454,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 5 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 0 Underlying: Common Stock · 245,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 277,777 | $18.00 | $4,999,986.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · nonDerivative · entry 4 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 277,777 F4 · ownership.direct: The Reporting Person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the Reporting Person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the Reporting Person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the Reporting Person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the Reporting Person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionCommon Stock | 753,735 | $14.40 | $10,853,784.00 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · nonDerivative · entry 3 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 5,666,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionCommon Stock | 245,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 4,913,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers give effect to such conversion. The B-1 Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionCommon Stock | 4,668,046 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 4,668,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| August 26, 2020 Filed Aug 31, 2020 11:00 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | PurchaseCommon Stock | 365,241 | $4.25 | $1,552,274.25 |
DisclosureSEC source: 0001104659-20-100410 · tm2029838-2_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 793,635 F1 · kind: The reported securities were acquired by the Jack W. Schuler Living Trust. F2 · balance_after: The reported securities consist of the 759,616 shares of common stock owned by the Jack W. Schuler Living Trust, the 21 shares of common stock owned by the Renate Schuler Living Trust, and the 33,998 shares of common stock owned by the Schuler Family Foundation, in each case immediately following reported transaction. F3 · ownership.nature: Jack W. Schuler has an indirect pecuniary interest the reported securities through (i) the Jack W. Schuler Living Trust, as its trustee and beneficiary, (ii) the Renate Schuler Living Trust, as the spouse of its trustee and beneficiary, and (iii) the Schuler Family Foundation, as its president. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:25 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | PurchaseCommon Stock, par value $0.001 | 2,285,715 | $3.50 | $8,000,002.50 |
DisclosureSEC source: 0000905148-20-000769 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,394,517 F1 · ownership.nature: These shares of common stock are directly held by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| June 26, 2020 Filed Jun 26, 2020 23:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 2,424,242 | $1.65 | $3,999,999.30 |
DisclosureSEC source: 0000899243-20-017808 · doc4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,157,042 F1 · shares: The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on June 26, 2020. F3 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| June 26, 2020 Filed Jun 26, 2020 23:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 5,151,517 | $1.65 | $8,500,003.05 |
DisclosureSEC source: 0000899243-20-017808 · doc4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,368,862 F1 · shares: The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on June 26, 2020. F2 · ownership.nature: The shares are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| June 22, 2020 Filed Nov 3, 2020 23:21 UTC | BIODESIX INC BDSX · Entity 6053 | Grant3% Convertible Debt due June 2021 · Derivative | Not disclosed | $0.00 | $1,546,681.28 |
DisclosureSEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 13 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: Not disclosed Underlying: Common Stock · 108,564 shares Expires 2021-06-30 F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 15:30 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 95,492 | $9.86 | $941,551.12 |
DisclosureSEC source: 0001628280-20-009594 · wf-form4_159242222607599.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 16,603,524 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.93 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 15:32 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 134,080 | $9.34 | $1,252,307.20 |
DisclosureSEC source: 0001628280-20-009503 · wf-form4_159233594118010.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 16,508,032 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.07 to $9.50, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 15:35 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 129,000 | $9.18 | $1,184,220.00 |
DisclosureSEC source: 0001628280-20-009429 · wf-form4_159224973794360.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 16,373,952 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.94 to $9.35, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 15:28 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 100,000 | $9.84 | $984,000.00 |
DisclosureSEC source: 0001628280-20-009333 · wf-form4_159199011999222.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 16,244,952 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.38 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 10, 2020 Filed Jun 13, 2020 00:32 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 339,083 | $1.97 | $666,806.72 |
DisclosureSEC source: 0000899243-20-016438 · doc4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,071,883 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.92 to $2.00. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate purchase price. F2 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 15:36 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 180,955 | $9.63 | $1,742,596.65 |
DisclosureSEC source: 0001628280-20-009259 · wf-form4_159190414579078.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 16,144,952 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.30 to $9.89, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 01:32 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | OtherWarrants (Right to buy) · Derivative | 730,560 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000905148-20-000694 · form4.xml · derivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 730,560 shares Expires 2020-06-09 F1 · ownership.nature: These shares of common stock are directly held by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 01:32 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | OtherCommon Stock, par value $0.001 | 730,560 | $1.80 | $1,315,008.00 |
DisclosureSEC source: 0000905148-20-000694 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,108,802 F1 · ownership.nature: These shares of common stock are directly held by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 14:49 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 1,100,000 | $8.58 | $9,438,000.00 |
DisclosureSEC source: 0001628280-20-009157 · wf-form4_159172857289069.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 15,963,997 F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 05, 2020 Filed Oct 5, 2021 16:01 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 54,975 | $9.08 | $499,173.00 |
DisclosureSEC source: 0001628280-21-019655 · wf-form4_163346401260762.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 54,975 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.97 to $9.22, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:14 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030271 · doc4.xml · derivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. F4 · derivative.expiration_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:14 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030271 · doc4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,103,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. F2 · balance_after: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any. Read SEC document |
| May 14, 2020 Filed Jul 16, 2021 17:18 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 29,577 | $9.20 | $272,108.40 |
DisclosureSEC source: 0001628280-21-013967 · wf-form4_162647031767123.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 16,633,101 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.97 to $9.40, inclusive. The reporting person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 13, 2020 Filed May 15, 2020 16:21 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 89,055 | $9.46 | $842,460.30 |
DisclosureSEC source: 0001628280-20-007895 · wf-form4_158957404422286.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,863,997 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.09 to $9.60, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 12, 2020 Filed May 14, 2020 15:39 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 20,000 | $9.92 | $198,400.00 |
DisclosureSEC source: 0001628280-20-007777 · wf-form4_158948516369338.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,774,942 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.85 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 12, 2020 Filed May 14, 2020 19:57 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029384 · doc4.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040 Underlying: Common Stock · 1,040 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F4 · derivative.exercise_date: The restricted stock units vest on May 12, 2021. F4 · derivative.expiration_date: The restricted stock units vest on May 12, 2021. Read SEC document |
| May 12, 2020 Filed May 14, 2020 19:57 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 82 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029384 · doc4.xml · derivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82 Underlying: Common Stock · 82 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on May 12, 2021. F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on May 12, 2021. Read SEC document |
| May 12, 2020 Filed May 14, 2020 19:57 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Converted) · Derivative | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029384 · doc4.xml · derivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273 Underlying: Common Stock · 273 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 12, 2020. F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 12, 2020. Read SEC document |
| May 11, 2020 Filed May 13, 2020 15:18 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 20,000 | $9.99 | $199,800.00 |
DisclosureSEC source: 0001628280-20-007665 · wf-form4_158939746508444.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,754,942 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.96 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 07, 2020 Filed May 11, 2020 15:44 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 25,000 | $9.87 | $246,750.00 |
DisclosureSEC source: 0001628280-20-007417 · wf-form4_158922627188967.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,734,942 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.66 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 06, 2020 Filed May 8, 2020 15:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 10,868 | $10.00 | $108,680.00 |
DisclosureSEC source: 0001628280-20-007187 · wf-form4_158896443398136.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,709,942 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.98 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:19 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 8,625 | $10.00 | $86,250.00 |
DisclosureSEC source: 0001628280-20-006957 · wf-form4_158888272517909.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,699,074 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 04, 2020 Filed May 6, 2020 15:29 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 1,204 | $9.98 | $12,015.92 |
DisclosureSEC source: 0001628280-20-006666 · wf-form4_158879334450372.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,690,449 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $9.99, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 01, 2020 Filed May 5, 2020 15:21 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 4,000 | $10.03 | $40,120.00 |
DisclosureSEC source: 0001628280-20-006412 · wf-form4_158870650017962.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,689,245 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.96 to $10.36, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 15:40 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 5,001 | $10.00 | $50,010.00 |
DisclosureSEC source: 0001628280-20-005729 · wf-form4_158810281787536.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,685,245 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.99 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 15:25 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 81,621 | $9.90 | $808,047.90 |
DisclosureSEC source: 0001628280-20-005503 · wf-form4_158801550473372.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,680,244 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.68 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 15:39 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 157,688 | $9.47 | $1,493,305.36 |
DisclosureSEC source: 0001628280-20-005425 · wf-form4_158775712523702.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,598,623 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.11 to $9.67, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 15:36 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 79,650 | $9.01 | $717,646.50 |
DisclosureSEC source: 0001628280-20-005370 · wf-form4_158767054627987.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,440,935 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.77 to $9.35, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 15:17 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 59,357 | $9.40 | $557,955.80 |
DisclosureSEC source: 0001628280-20-005260 · wf-form4_158758303935067.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 14,361,285 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.26 to $9.60, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 14, 2020 Filed Apr 14, 2020 20:11 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GiftCommon Stock | 1,100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-004973 · wf-form4_158690945159643.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,077,023 F1 · kind: The Schuler Family Foundation gifted 1,100,000 shares to a single unaffiliated charitable foundation. The Schuler Family Foundation disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.